Insmed to Present at the JMP Securities Healthcare Conference
20 Juin 2014 - 2:55PM
Marketwired
Insmed to Present at the JMP Securities Healthcare Conference
Company Presentation Scheduled for Tuesday, June 24th at 1:30
p.m. Eastern time
MONMOUTH JUNCTION, NJ--(Marketwired - Jun 20, 2014) - Insmed
Incorporated (NASDAQ: INSM) today announced that Company management
will participate at the JMP Securities Healthcare Conference taking
place June 24-25, 2014 at The Westin Grand Central in New York
City.
Will Lewis, President and Chief Executive Officer of Insmed,
will present a corporate overview on Tuesday, June 24th at 1:30
p.m. Eastern time. Mr. Lewis' presentation will be webcast
live on the internet and can be accessed by visiting the Investor
Relations section of the Company's website at www.insmed.com. A
replay of the webcast will be archived on the Insmed website for 90
days following the presentation.
About Insmed Insmed Incorporated is a biopharmaceutical company
dedicated to improving the lives of patients battling serious lung
diseases. Insmed is focused on the development and
commercialization of ARIKAYCE™, or liposomal amikacin for
inhalation, for at least two identified orphan patient populations:
patients with nontuberculous mycobacteria (NTM) lung infections and
cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung
infections. For more information, please visit www.insmed.com.
Forward-looking Statements This release contains forward-looking
statements. Words, and variations of words, such as "intend,"
"expect," "will," "anticipate," "believe," "continue," "propose"
and similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in
this release, including statements relating to the status, results
and timing of clinical trials and clinical data, the anticipated
benefits of Insmed's products, the anticipated timing of regulatory
submissions, and the ability to obtain required regulatory
approvals, bring products to market and successfully commercialize
products constitute forward-looking statements that involve risks
and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. Such
risks and uncertainties include, without limitation, failure or
delay of European, Canadian, U.S. Food and Drug Administration and
other regulatory reviews and approvals, competitive developments
affecting the Company's product candidates, delays in product
development or clinical trials or other studies, patent disputes
and other intellectual property developments relating to the
Company's product candidates, unexpected regulatory actions, delays
or requests, the failure of clinical trials or other studies or
results of clinical trials or other studies that do not meet
expectations, the fact that subsequent analyses of clinical trial
or study data may lead to different (including less favorable)
interpretations of trial or study results or may identify important
implications of a trial or study that are not reflected in
Company's prior disclosures, and the fact that trial or study
results or subsequent analyses may be subject to differing
interpretations by regulatory agencies, the inability to
successfully develop the Company's product candidates or receive
necessary regulatory approvals, the inability to make product
candidates commercially successful, changes in anticipated
expenses, changes in the Company's financing requirements or
ability to raise additional capital, and other risks and challenges
detailed in the Company's filings with the U.S. Securities and
Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2013 and its
subsequent quarterly reports on Form 10-Q. Investors are
cautioned not to place undue reliance on any forward-looking
statements that speak only as of the date of this news
release. The Company undertakes no obligation to update these
forward-looking statements to reflect events or circumstances or
changes in its expectations.
Contacts: LHA Anne Marie Fields Senior Vice President
212-838-3777 afields@lhai.com Bruce Voss Managing Director
310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024